This year, more than ever before, we’ve seen just how important it is for us all to stay connected and work together to build a stronger biotech ecosystem. In the face of great adversity, the biotech community has risen to the challenge and formed new collaborations and partnerships to innovate and rapidly develop new medicines and tools to help us beat this pandemic.
COVID-19 has created significant challenges for the Venture Capital (VC) market and life science companies seeking funding during the pandemic. While the pandemic has undoubtedly added a new layer of risk to an inherently risky field, the fundamentals for what makes a company attractive to a VC have remained steady.
Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.
Dr. Sklavos joins Arcellx with over 15 years of experience in biomedical and clinical research in academic, government and industry settings. Dr. Sklavos brings broad drug development expertise to Arcellx as a result of managing multiple complex projects and portfolios comprised of various drug modalities including monoclonal and bispecific antibodies, antibody drug conjugates, peptide conjugates, and cell therapies.
BioHealth Capital Region Startups Raised More Than $739M in 2019 These 15 Biohealth Startups had a Banner Year, Setting Themselves Up for Success in 2020 The startup ecosystem in the [….]
Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform
Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform With new funding, Arcellx furthers its cell therapy platform intended to address new therapies in [….]
Five Cell and Gene Therapy Companies that Are Changing the Landscape of the Field